Theresa Grasing
Physician Assistant · Annapolis, MDNPI 1245757103
Payments from drug & device makers
Across 263 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$517
- Sanofi-aventis U.S. LLC$380
- Amneal Pharmaceuticals LLC$320
- AstraZeneca$272
- Bayer$254
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,400100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 59 | $1,236 |
| Novo Nordisk | 30 | $517 |
| Sanofi-aventis U.S. LLC | 17 | $380 |
| Amneal Pharmaceuticals LLC | 18 | $320 |
| AstraZeneca(2 entities) | 13 | $272 |
| Bayer | 12 | $254 |
| Dexcom, Inc. | 12 | $237 |
| Xeris Pharmaceuticals, Inc. | 12 | $211 |
| Radius Health, Inc. | 8 | $200 |
| Amgen(2 entities) | 9 | $180 |
| Boehringer Ingelheim | 7 | $165 |
| Insulet Corporation | 6 | $149 |
| Medtronic | 6 | $130 |
| Abbott | 6 | $115 |
| AbbVie | 5 | $110 |
| Cequr Corporation | 4 | $110 |
| Corcept Therapeutics | 4 | $94 |
| Tandem Diabetes Care, Inc. | 3 | $81 |
| Ascendis Pharma Endocrinology Inc | 3 | $70 |
| IBSA Pharma Inc. | 3 | $63 |
| Amphastar Pharmaceuticals, Inc. | 3 | $54 |
| BETA Bionics, Inc. | 2 | $48 |
| Ascensia Diabetes Care US Inc. | 2 | $43 |
| Sequel Med Tech, LLC | 2 | $39 |
| Nevro Corp. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $36 |
| Novartis | 1 | $32 |
| Enterra Medical, Inc. | 1 | $30 |
| Mannkind Corporation | 2 | $29 |
| Globus Medical | 2 | $28 |
| Embecta Corp. | 1 | $25 |
| Pfizer | 1 | $24 |
| BD | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| RGH Enterprises LLC | 1 | $15 |
| Lifescan, Inc. | 1 | $15 |
| Merck | 1 | $15 |
How this compares
$5,420 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $215,644 |
| MounjaroTirzepatide | 59 | $104,767 |
| JardianceEmpagliflozin | 63 | $76,403 |
| RybelsusSemaglutide | 22 | $45,439 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 60 | $39,584 |
| TrulicityDulaglutide | 15 | $32,698 |
| FarxigaDapagliflozin Propanediol | 17 | $25,408 |
| JanuviaSitagliptin Phosphate | 22 | $25,309 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $17,602 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $16,580 |
| Humalog Kwikpen U-100Insulin Lispro | 37 | $15,449 |
| Admelog SolostarInsulin Lispro | 12 | $11,487 |
| HumalogInsulin Lispro | 30 | $10,786 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $8,694 |
| SynthroidLevothyroxine Sodium | 87 | $7,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $517 | $261,083125 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,236 | $148,251104 claims |
| Boehringer IngelheimJardiance | $165 | $76,40363 claims |
| AstraZenecaFarxiga | $272 | $25,40817 claims |
| MerckJanuvia | $15 | $25,30922 claims |
| AbbVieSynthroid | $110 | $7,71487 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $320 | $3,688270 claims |
| Sanofi-aventis U.S. LLCLantus | $380 | $1,78412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.
Other physician assistant in Annapolis
- Lisa FoxAnnapolis$26K
- Clifford AmosAnnapolis$21K
- Andrew MarsellaAnnapolis$18K
- Julie CatlinAnnapolis$18K
- Melissa VeneracionAnnapolis$16K
- Nathan TurnerAnnapolis$11K
- Margaret JoyceTowson$220K
- Kara CossisBaltimore$177K
- Michael RitmillerOwings Mills$92K
- Garland JamesSilver Spring$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.